Search

Your search keyword '"Price, Douglas A."' showing total 783 results
Start Over Author "Price, Douglas A."
783 results on '"Price, Douglas A."'

3. List of Contributors

Author

Agrawal, Pankaj B., primary, Akhtar, Yasmin, additional, Alallah, Jubara, additional, Alhassen, Ziad, additional, Altit, Gabriel, additional, AlZubaidi, Abbas, additional, Amlani, Lahin M., additional, Antelo, Martin, additional, Athalye-Jape, Gayatri, additional, Badarch, Jargalsaikhan, additional, Baer, Gerri, additional, Bagga, Nitasha, additional, Bahr, Timothy M., additional, Bar-Cohen, Yaniv, additional, M. Barr, Stephanie, additional, Bauer, Andrew J., additional, Bearer, Cynthia F., additional, Beckman, Ross M., additional, Beltempo, Marc, additional, Bembea, Melania M., additional, Berlin, Sheila, additional, Berry, Shandeigh N., additional, Bhandari, Vineet, additional, Bhatia, Shaifali, additional, Bhombal, Shazia, additional, Bigelow, Elaine O., additional, Blevins, Carley, additional, Boppana, Suresh, additional, Boss, Renee, additional, Brooks, Sandra, additional, Buonocore, Giuseppe, additional, Burnsed, Jennifer, additional, Calabria, Andrew C., additional, Carrasco, Melisa, additional, Carter, Brian S., additional, Chandrasekharan, Praveen, additional, Chavez-Valdez, Raul, additional, Choleva, Lauryn, additional, Christensen, Robert D., additional, Chung, Wendy K., additional, Coggins, Sarah A., additional, Cooke, David W., additional, Cummings, Laura, additional, Currie, Erin R., additional, Davidson, Joanne O., additional, Davis, Jonathan M., additional, Day-Richardson, Colby L., additional, De Leon, Diva D., additional, Dedhia, Kavita, additional, Dendi, Alvaro, additional, Deshpande, Anita, additional, Dionne, Janis M., additional, Donda, Keyur, additional, Donohue, Lee, additional, Doyle, Jefferson J., additional, Dulkerian, Susan J., additional, Dumpa, Vikramaditya, additional, Duncan, Andrea F., additional, Dunham, Alexandra M., additional, Ecret, DiAnn, additional, Ellis, Kelstan, additional, El-Metwally, Dina, additional, Etchill, Eric W., additional, Ethawi, Yahya, additional, Everett, Allen D., additional, Fabres, Jorge, additional, Felling, Ryan J., additional, Fenton, Tanis R., additional, Flannery, Dustin D., additional, Flynn, Joseph T., additional, Fredenburg, Michaelene, additional, Fuqua, John, additional, Garcia, Alejandro V., additional, Garzon, Steven, additional, Gauda, Estelle B., additional, Thompson, Marisa Gilstrop, additional, Goldenberg, Barton, additional, Salazar, Andres J. Gonzalez, additional, Goodwin, Julie E., additional, Goudy, Steven L., additional, Graham, Ernest, additional, Grauerholz, Kathryn, additional, Groves, Mari L., additional, Guillot, Mireille, additional, Gunn, Alistair J., additional, Gupta, Arjun, additional, Hackam, David J., additional, Hidalgo, Joaquin, additional, Honcharuk, Erin, additional, Htun, Zeyar, additional, Hudak, Mark L., additional, Driscoll, Colleen A. Hughes, additional, Huisman, Thierry A.G.M., additional, Jabroun, Mireille, additional, Jackson, Eric M., additional, Jain, Naveen, additional, Jain, Rajesh, additional, Jelin, Angie, additional, Jelin, Eric, additional, Juul, Sandra E., additional, Kaufman, David A., additional, BMBS, Alison Kent,, additional, Khuder, Sundos, additional, Kovler, Mark L., additional, Kraus, Courtney L., additional, Krishnamurthy, Ganga, additional, Kukora, Stephanie K., additional, Kumar, Ashok, additional, Kunisaki, Shaun M., additional, Kuper-Sassé, Margaret, additional, Kwiatkowski, David M., additional, Lakshminrusimha, Satyan, additional, Laventhal, Naomi T., additional, Lawrence, Shelley M., additional, Lee-Winn, Angela E., additional, Leuthner, Steven, additional, Lewallen, Laura, additional, Lewis, Tamorah R., additional, Liken, Hillary B., additional, Liubšys, Arūnas, additional, Lui, Kei, additional, Maheshwari, Akhil, additional, Maitre, Nathalie L., additional, Makker, Kartikeya, additional, Mammen, Cherry, additional, J. Martin, Richard, additional, Mattos Castellano, María, additional, Maxwell, Jessie R., additional, McFarlane, Renske, additional, McLemore, Gabrielle, additional, McNelis, Kera M., additional, McPherson, Christopher, additional, Mietzsch, Ulrike, additional, Milante, Rachel R., additional, Miller, Jena L., additional, Mukhopadhyay, Sagori, additional, Mynak, Mimi L., additional, Nasr, Isam W., additional, Natarajan, Niranjana, additional, Navaneethan, Hema, additional, Nees, Shannon N., additional, Nguyen, Mai, additional, Noori, Shahab, additional, Odackal, Namrita J., additional, Ohls, Robin K., additional, Ostrander, Betsy E., additional, Pammi, Mohan, additional, Parimi, Prabhu S., additional, Park, Albert, additional, Patil, Monika S., additional, Pereira, Elaine M., additional, Premkumar, Muralidhar H., additional, Price-Douglas, Webra, additional, Puopolo, Karen M., additional, Rabe, Heike, additional, M. Rahman, Mohammad, additional, Reber, Kristina, additional, Kallem, Venkat Reddy, additional, Repka, Michael X., additional, Rhee, Daniel S., additional, Ringle, Megan L., additional, Rohrer, Allison, additional, Romero, Christopher J., additional, Ryan, Marisa A., additional, Sampah, Maame E.S., additional, Sanchez-Valle, Amarilis, additional, Sant’Anna, Guilherme M., additional, Saugstad, Ola D., additional, RobertH., Anne and, additional, Schacht, John P., additional, Schelonka, Robert L., additional, Schofield, Erin E., additional, Selewski, David T., additional, Shah, Prakesh S., additional, Shih, Jessica G., additional, Sibinga, Erica M.S., additional, Sigal, Winnie, additional, Sims, Brian, additional, Singh, Rachana, additional, Singh, Srijan, additional, Snyder, Donna, additional, Sobrero, Helena, additional, Sponseller, Paul D., additional, Stafstrom, Carl E., additional, Steflik, Heidi J., additional, Sun, Lisa R., additional, Sundararajan, Sripriya, additional, Taylor, Sarah N., additional, Terrin, Norma, additional, Thacker, Prolima G., additional, Thébaud, Bernard, additional, Toms, Rune, additional, Torres, Benjamin A., additional, Tunkel, David E., additional, Umandap, Christine H., additional, Chaves, Diana Vargas, additional, Vento, Maximo, additional, Walsh, Jonathan, additional, Walter, Jolan, additional, Weaver, Meaghann S., additional, Weimer, Kristin, additional, Weller, Jennine, additional, Winter, Lindy W., additional, Wu, Tai-Wei, additional, and Yau, Mabel, additional

Published
2024
Full Text
View/download PDF

4. A Benefit-Cost Analysis of Tulsa Pre-K, Based on Effects on High School Graduation and College Attendance. Policy Paper No. 2022-029

Author

W.E. Upjohn Institute for Employment Research, Bartik, Timothy J., Gormley, William, Amadon, Sara, Hummel-Price, Douglas, and Fuller, James

Abstract

This paper presents new benefit-cost estimates for the Tulsa universal preschool program. These calculations are based on estimated effects from previous papers of Tulsa pre-K on high school graduation rates and college attendance rates of students who were enrolled in kindergarten in Tulsa Public Schools in the fall of 2006. In this paper, educational effects from these prior papers are used to infer lifetime earnings effects and are compared with program costs. Our conservative estimates of earnings effects suggest that per pre-K participant, the present value of earnings effects in 2021 dollars is $25,533, compared with program costs of $9,628, for a benefit-cost ratio of 2.65. Compared to prior benefit-cost studies of Tulsa pre-K, this benefit-cost ratio is below what was predicted from Tulsa pre-K's estimated effects on kindergarten test scores, but above what was predicted from Tulsa pre-K's estimated effects on grade retention by ninth grade. This fading and recovery of predicted pre-K effects as children go through K-12 and then enter adulthood is consistent with prior research. It attests to the importance of the "soft skill" effects of pre-K and reminds us that short-term studies of pre-K provide useful information for public-policy decisions.

Published
2022
Full Text
View/download PDF

6. Does Early Childhood Education Help to Improve High School Outcomes? Results from Tulsa

Author

Amadon, Sara, Gormley, William T., Claessens, Amy, Magnuson, Katherine, Hummel-Price, Douglas, and Romm, Katelyn

Abstract

Early childhood education contributes to improved school readiness but impacts on high school remain unclear. This study estimates the effects of Tulsa, Oklahoma's universal pre-K and Head Start programs through the junior year of high school (in 2018/2019; N = 2902; M[subscript age] = 16.52, SD = 0.39; 48% female; 28% white, 34% Black, 27% Hispanic, 8% Native American). Propensity score weighted regressions suggest students who attended pre-K, but not Head Start, missed less school, were less likely to fail courses and be retained in grade, were more likely to take an Advanced Placement/International Baccalaureate course, but did not have higher test scores or grades. Subgroup analyses by race/ethnicity demonstrated some differences in the pattern of associations favoring students of color.

Published
2022
Full Text
View/download PDF

9. Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3

Author

Lee, Kristi Y., primary, Beatson, Erica L., additional, Knechel, Martina A., additional, Sommer, Elijah R., additional, Napoli, Giulia C., additional, Risdon, Emily N., additional, Leon, Andres F., additional, Depaz, Roger D., additional, Strope, Jonathan D., additional, Price, Douglas K., additional, Chau, Cindy H., additional, and Figg, William D., additional

Published
2024
Full Text
View/download PDF

12. Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.

Author

Beatson, Erica L., Risdon, Emily N., Napoli, Giulia C., Price, Douglas K., Chau, Cindy H., and Figg, William D.

Subjects
DNA repair, CELL lines, PROSTATE cancer, TUMOR suppressor genes, CANCER cells, PROSTATE cancer patients
Abstract

As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at the genomic level. Our study investigated the genomic characterization of eight PCa cell lines to understand which models are clinically relevant. We designed a custom AmpliSeq DNA gene panel that encompassed key molecular pathways targeting AR signaling, apoptosis, DNA damage repair, and PI3K/AKT/PTEN, in addition to tumor suppressor genes. We examined the relationship between cell line genomic alterations and therapeutic response. In addition, using DepMap's Celligner tool, we identified which preclinical models are most representative of specific prostate cancer patient populations on cBioPortal. These data will help investigators understand the genetic differences in preclinical models of PCa and determine which ones are relevant for use in their translational research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease

Author

Hoque, Ashraful, Yao, Song, Till, Cathee, Kristal, Alan R, Goodman, Phyllis J, Hsing, Ann W, Tangen, Catherine M, Platz, Elizabeth A, Stanczyk, Frank Z, Reichardt, Juergen KV, vanBokhoven, Adrie, Neuhouser, Marian L, Santella, Regina M, Figg, William D, Price, Douglas K, Parnes, Howard L, Lippman, Scott M, Ambrosone, Christine B, and Thompson, Ian M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Urologic Diseases, Aging, Cancer, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Androstenedione, Case-Control Studies, Double-Blind Method, Finasteride, Humans, Male, Middle Aged, Neoplasm Grading, Prostatic Neoplasms, Risk Assessment, Urology & Nephrology, Clinical sciences
Abstract

ObjectiveTo evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione) and its association with prostate cancer risk among subjects who participated in the Prostate Cancer Prevention Trial.MethodsWe analyzed serum androstenedione levels in 317 prostate cancer cases and 353 controls, nested in the Prostate Cancer Prevention Trial, a randomized placebo-controlled trial that found finasteride decreased prostate cancer risk. Androstenedione is the second most important circulating androgen in men besides testosterone and also a substrate for 5α-reductase enzyme.ResultsWe observed a 22% increase in androstenedione levels compared with the baseline values in subjects who were treated with finasteride for 3 years. This significant increase did not vary by case-control status. Adjusted odds ratio and 95% confidence interval for the third tertile of absolute change in androstenedione levels compared with the first tertile were 0.42 (95% confidence interval, 0.19-0.94) for low-grade (Gleason score

Published
2015

16. GNRH2Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy

Author

SISSUNG, TRISTAN M., primary, LOCHRIN, SARAH, additional, LIU, TYLER, additional, SCHMIDT, KEITH, additional, STROPE, JONATHAN, additional, RISDON, EMILY, additional, CHOO-WOSOBA, HYOYOUNG, additional, VENZON, DAVID J., additional, LASSOUED, WIEM, additional, SATER, HOUSSEIN A., additional, WALTER-RODRIGUEZ, BEATRIZ, additional, PRICE, DOUGLAS K., additional, and FIGG, WILLIAM D., additional

Published
2023
Full Text
View/download PDF

17. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

Author

Petrovics, Gyorgy, Price, Douglas K., Lou, Hong, Chen, Yongmei, Garland, Lisa, Bass, Sara, Jones, Kristine, Kohaar, Indu, Ali, Amina, Ravindranath, Lakshmi, Young, Denise, Cullen, Jennifer, Dorsey, Tiffany H., Sesterhenn, Isabell A., Brassell, Stephen A., Rosner, Inger L., Ross, Doug, Dahut, William, Ambs, Stefan, Figg, William Douglas, Srivastava, Shiv, and Dean, Michael

Published
2019
Full Text
View/download PDF

19. Figure S4 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Author

Sissung, Tristan M., primary, Ley, Ariel M., primary, Strope, Jonathan D., primary, McCrea, Edel M., primary, Beedie, Shaunna, primary, Peer, Cody J., primary, Shukla, Suneet, primary, van Velkinburgh, Jennifer, primary, Reece, Kelie, primary, Troutman, Sarah, primary, Campbell, Tessa, primary, Fernandez, Elena, primary, Huang, Phoebe, primary, Smith, Jordan, primary, Thakkar, Nilay, primary, Venzon, David J., primary, Brenner, Stefan, primary, Lee, Wooin, primary, Merino, Maria, primary, Luo, Ji, primary, Jager, Walter, primary, Price, Douglas K., primary, Chau, Cindy H., primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

20. Data from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Author

Sissung, Tristan M., primary, Ley, Ariel M., primary, Strope, Jonathan D., primary, McCrea, Edel M., primary, Beedie, Shaunna, primary, Peer, Cody J., primary, Shukla, Suneet, primary, van Velkinburgh, Jennifer, primary, Reece, Kelie, primary, Troutman, Sarah, primary, Campbell, Tessa, primary, Fernandez, Elena, primary, Huang, Phoebe, primary, Smith, Jordan, primary, Thakkar, Nilay, primary, Venzon, David J., primary, Brenner, Stefan, primary, Lee, Wooin, primary, Merino, Maria, primary, Luo, Ji, primary, Jager, Walter, primary, Price, Douglas K., primary, Chau, Cindy H., primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Figure Legends from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Author

Sissung, Tristan M., primary, Ley, Ariel M., primary, Strope, Jonathan D., primary, McCrea, Edel M., primary, Beedie, Shaunna, primary, Peer, Cody J., primary, Shukla, Suneet, primary, van Velkinburgh, Jennifer, primary, Reece, Kelie, primary, Troutman, Sarah, primary, Campbell, Tessa, primary, Fernandez, Elena, primary, Huang, Phoebe, primary, Smith, Jordan, primary, Thakkar, Nilay, primary, Venzon, David J., primary, Brenner, Stefan, primary, Lee, Wooin, primary, Merino, Maria, primary, Luo, Ji, primary, Jager, Walter, primary, Price, Douglas K., primary, Chau, Cindy H., primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

22. Table S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Author

Sissung, Tristan M., primary, Ley, Ariel M., primary, Strope, Jonathan D., primary, McCrea, Edel M., primary, Beedie, Shaunna, primary, Peer, Cody J., primary, Shukla, Suneet, primary, van Velkinburgh, Jennifer, primary, Reece, Kelie, primary, Troutman, Sarah, primary, Campbell, Tessa, primary, Fernandez, Elena, primary, Huang, Phoebe, primary, Smith, Jordan, primary, Thakkar, Nilay, primary, Venzon, David J., primary, Brenner, Stefan, primary, Lee, Wooin, primary, Merino, Maria, primary, Luo, Ji, primary, Jager, Walter, primary, Price, Douglas K., primary, Chau, Cindy H., primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure S1 from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

30. Data from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Methods from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Results from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table S1 from Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy

Author

Best, Carolyn J.M., primary, Gillespie, John W., primary, Yi, Yajun, primary, Chandramouli, Gadisetti V.R., primary, Perlmutter, Mark A., primary, Gathright, Yvonne, primary, Erickson, Heidi S., primary, Georgevich, Lauren, primary, Tangrea, Michael A., primary, Duray, Paul H., primary, González, Sergio, primary, Velasco, Alfredo, primary, Linehan, W. Marston, primary, Matusik, Robert J., primary, Price, Douglas K., primary, Figg, William D., primary, Emmert-Buck, Michael R., primary, and Chuaqui, Rodrigo F., primary

Published
2023
Full Text
View/download PDF

39. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

Author

Norris, John D., Ellison, Stephanie J., Baker, Jennifer G., Stagg, David B., Wardell, Suzanne E., Park, Sunghee, Alley, Holly M., Baldi, Robert M., Yllanes, Alexander, Andreano, Kaitlyn J., Stice, James P., Lawrence, Scott A., Eisner, Joel R., Price, Douglas K., Moore, William R., Figg, William D., and McDonnell, Donald P.

Subjects
Cytochrome P-450 -- Health aspects, Prostate cancer -- Care and treatment -- Physiological aspects, Androgens -- Health aspects, Health care industry
Abstract

The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC). Recently, however, it has been reported that CYP17 inhibitors can interact directly with the androgen receptor (AR). A phase I study recently reported that seviteronel, a CYP17 lyase-selective inhibitor, aedemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another study showed seviteronel's direct effects on AR function. This suggested that seviteronel may have therapeutically relevant activities in addition to its ability to inhibit androgen production. Here, we have demonstrated that CYP17 inhibitors, with the exception of orteronel, can function as competitive AR antagonists. Conformational profiling revealed that the CYP17 inhibitor-bound AR adopted a conformation that resembled the unliganded AR (apo-AR), precluding nuclear localization and DNA binding. Further, we observed that seviteronel and abiraterone inhibited the growth of tumor xenografts expressing the clinically relevant mutation AR-F876L and that this activity could be attributed entirely to competitive AR antagonism. The results of this study suggest that the ability of CYP17 inhibitors to directly antagonize the AR may contribute to their clinical efficacy in CRPC., Introduction Prostate cancer is the most common cancer diagnosed in men in the United States and the second-leading cause of cancer-related deaths (1). It is well established that prostate tumors [...]

Published
2017
Full Text
View/download PDF

46. RainCube and Its Initial Post-Launch Operations

Author

Williams, Austin, Chahat, Nacer, Sander, Jonathan, Price, Douglas, Statham, Shannon, Imken, Travis, Tanelli, Simone, Im, Eastwood, and Peral, Eva

Abstract

UNKNOWN

Published
2018

50. PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials

Author

Beatson, Erica L, Chau, Cindy H, Price, Douglas K, and Figg, William D

Subjects
Original Article
Abstract

PARP inhibitors were recently introduced as a novel targeted therapy for biomarker positive metastatic castration resistant prostate cancer (mCRPC) patients, a population that inevitably acquires resistance to existing standard care regimens. Olaparib and rucaparib are now FDA-approved for mCRPC, while talazoparib and niraparib are advancing through the clinical stage of development. We highlight the recent results of the GALAHAD trial testing the efficacy of niraparib in mCRPC patients with DNA damage repair gene defects and compare its performance to key PARP inhibitor trials (PROFOUND, olaparib; TRITON2, rucaparib; TALAPRO-1, talazoparib). Finally, we briefly discuss recent updates on emerging PARP inhibitor and androgen receptor targeting combination trials as a novel treatment strategy for upfront treatment of mCRPC and in earlier disease settings.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results